drug_type
RELEVANT_DRUG
intervention_type
Biological; gene-modified T-cell therapy (CAR-T)
drug_description
Universal (allogeneic) chimeric antigen receptor T cells engineered to target BCMA (TNFRSF17) to ablate BCMA-expressing plasmablasts and long‑lived plasma cells, aiming to reduce autoantibody production in lupus nephritis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells engineered with a chimeric antigen receptor targeting BCMA (TNFRSF17) recognize and kill BCMA-expressing plasmablasts and long-lived plasma cells via CAR-mediated cytotoxicity, depleting antibody-secreting cells and reducing pathogenic autoantibody production in lupus nephritis.
drug_name
BCMA CAR-T cells
nct_id_drug_ref
NCT06681337